Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

COVID-19 3Severe Acute Respiratory Syndrome 1Papillomavirus Infections 1Multiple Myeloma 1Mastocytosis 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 35Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 23Papillomavirus Vaccines 14Data Collection 7Blood Specimen Collection 7Vaccines 6Vaccines, Synthetic 5Educational Status 5Radiotherapy, Intensity-Modulated 4Human Papillomavirus Recombinant Vaccine nonavalent 4Early Intervention, Educational 4Vaginal Smears 3Surveys and Questionnaires 3Polymerase Chain Reaction 3Paclitaxel 3Methods 3Engerix-B 3Colposcopy 3Cisplatin 3halofantrine 2fludarabine phosphate 2fludarabine 2aldesleukin 2Watchful Waiting 2Taxes 2Patient Navigation 2Papanicolaou Test 2Observation 2Light Coagulation 2Imiquimod 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Papillomavirus Infections × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡